GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription ...

Investing.com - 市值17.8亿美元的GoodRx Holdings Inc. (NASDAQ: GDRX )在周二美祖证券的研究报告中维持"中性"评级和5.00美元的目标价。该股近期表现强劲，过去一周上涨超过46%。根据 InvestingPro 分析，该公司的整体财务健康状况被评为"优秀"。

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

Investing.com - 美国银行证券 (BofA Securities)在GoodRx Holdings Inc. (NASDAQ: GDRX )最新产品公告后，维持其"表现不佳"评级和3.40美元的目标价。根据 InvestingPro 数据，该股目前交易价格为5.07美元，分析师目标价范围从3.40美元到7.00美元不等，表明尽管公司拥有93.68%的高毛利率，市场情绪仍然喜忧参半。

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

GoodRx（GDRX.US）公司简介：GoodRx Holdings Inc是一家以消费者为中心，旨在降低美国的医疗成本的数字医疗平台。公司运营着一个价格比较平台，为消费 ...

Goodrx Holdings Inc.（GDRX）一度上涨超过38.87%，有望创2023年7月31日（当天收涨36.89%、盘中一度上涨38.81%）以来最佳单日表现。该公司与诺和诺德合作，在美国医药市场供应后者的药品。诺和诺德宣布，下调Ozempic的价格。

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx（GDRX.US）公司简介：GoodRx Holdings Inc是一家以消费者为中心，旨在降低美国的医疗成本的数字医疗平台。公司运营着一个价格比较平台，为消费 ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...